GCV Symposium 2017
Skip Content

26 December 2014

12 spin-outs of Christmas: Circassia

After the largest British biotech IPO in years, Imperial's Circassia makes our festive spin-out list.

Author: Gregg Bayes-Brown, editor

Circassia

Institution: Imperial College London

Sector: Allergy Treatments

 

The scope for allergy treatments such as cat allergies and hay fever is estimated to be a $12bn global market.

In the largest UK biotech floatation this side of the millennium, Imperial College London spin-out Circassia brought in $332m in its March IPO. Trading at the top of its range, the IPO saw ICL’s tech transfer unit Imperial Innovations deliver over a three-fold return on investment for its £25.5m ($42.64m) stake, now worth £82m. Circassia’s primary products are focused on treating common allergies, such as cat allergy and hay fever.

Although it is now trading publically, the future looks bright for Circassia. Should it received the FDA approval the company is now aiming for, its cat allergy treatment alone will be on the way to providing relief to 24 million people in the US. 

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed
Trial Subscribe now

Latest Magazine

GCV Symposium 2017

Editor’s picks

Most popular

Events

23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.